CN118043075A - 用于治疗kras突变体癌症的方法和组合物 - Google Patents

用于治疗kras突变体癌症的方法和组合物 Download PDF

Info

Publication number
CN118043075A
CN118043075A CN202280059341.9A CN202280059341A CN118043075A CN 118043075 A CN118043075 A CN 118043075A CN 202280059341 A CN202280059341 A CN 202280059341A CN 118043075 A CN118043075 A CN 118043075A
Authority
CN
China
Prior art keywords
kras
inhibitor
tini
administered
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280059341.9A
Other languages
English (en)
Chinese (zh)
Inventor
约翰·V·海马赫
雅克利内·P·罗比绍
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
Original Assignee
University of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System filed Critical University of Texas System
Publication of CN118043075A publication Critical patent/CN118043075A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202280059341.9A 2021-07-29 2022-07-29 用于治疗kras突变体癌症的方法和组合物 Pending CN118043075A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163227237P 2021-07-29 2021-07-29
US63/227,237 2021-07-29
PCT/US2022/074317 WO2023010121A1 (en) 2021-07-29 2022-07-29 Methods and compositions for treatment of kras mutant cancer

Publications (1)

Publication Number Publication Date
CN118043075A true CN118043075A (zh) 2024-05-14

Family

ID=85087345

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280059341.9A Pending CN118043075A (zh) 2021-07-29 2022-07-29 用于治疗kras突变体癌症的方法和组合物

Country Status (7)

Country Link
US (1) US20240374597A1 (https=)
EP (1) EP4376959A4 (https=)
JP (1) JP2024527109A (https=)
KR (1) KR20240051145A (https=)
CN (1) CN118043075A (https=)
CA (1) CA3227802A1 (https=)
WO (1) WO2023010121A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119607214A (zh) * 2025-02-17 2025-03-14 四川大学华西医院 Src抑制剂联合kras-g12c抑制剂用于制备治疗kras-g12c突变型肺癌的药物中的应用及药物组合物
WO2026077280A1 (zh) * 2024-10-12 2026-04-16 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） 包括nampt抑制剂和kras抑制剂的组合物及其用途

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025510572A (ja) 2022-03-08 2025-04-15 レボリューション メディシンズ インコーポレイテッド 免疫不応性肺癌を治療するための方法
CR20250420A (es) 2023-04-07 2025-11-20 Revolution Medicines Inc Inhibidores macrocíclicos de ras
AR132338A1 (es) 2023-04-07 2025-06-18 Revolution Medicines Inc Inhibidores de ras
CN121464140A (zh) 2023-04-14 2026-02-03 锐新医药公司 Ras抑制剂的结晶形式、含有其的组合物及其使用方法
CN121100123A (zh) 2023-04-14 2025-12-09 锐新医药公司 Ras抑制剂的结晶形式

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA202190749A1 (ru) * 2018-09-10 2021-07-09 Мирати Терапьютикс, Инк. Способы комбинированной терапии
JP7377679B2 (ja) * 2018-11-19 2023-11-10 アムジエン・インコーポレーテツド がん治療のためのｋｒａｓｇ１２ｃ阻害剤及び１種以上の薬学的に活性な追加の薬剤を含む併用療法
BR112021016149A2 (pt) * 2019-02-26 2021-10-13 Janssen Biotech, Inc. Terapias de combinação e estratificação de pacientes com anticorpos biespecíficos anti-egfr/c-met
WO2021148581A1 (en) * 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
KR20230028798A (ko) * 2020-06-25 2023-03-02 톨레모 테라퓨틱스 아게 암 치료를 위한 CBP/p300 브로모도메인 억제제 및 KRAS 억제제의 조합물
KR102379786B1 (ko) * 2020-08-13 2022-03-25 정부환 레일 형식 보행보조기구 방향전환장치

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026077280A1 (zh) * 2024-10-12 2026-04-16 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） 包括nampt抑制剂和kras抑制剂的组合物及其用途
CN119607214A (zh) * 2025-02-17 2025-03-14 四川大学华西医院 Src抑制剂联合kras-g12c抑制剂用于制备治疗kras-g12c突变型肺癌的药物中的应用及药物组合物

Also Published As

Publication number Publication date
CA3227802A1 (en) 2023-02-02
JP2024527109A (ja) 2024-07-19
US20240374597A1 (en) 2024-11-14
EP4376959A4 (en) 2025-06-11
EP4376959A1 (en) 2024-06-05
WO2023010121A1 (en) 2023-02-02
KR20240051145A (ko) 2024-04-19

Similar Documents

Publication Publication Date Title
CN118043075A (zh) 用于治疗kras突变体癌症的方法和组合物
US20250360208A1 (en) Use of glutamate modulating agents with immunotherapies to treat cancer
CN110996952A (zh) 用于治疗癌症的方法
JP6689400B2 (ja) チェックポイント阻害剤と組み合わされた腫瘍溶解性ウイルスによるがん療法
EP3760229A2 (en) Treatment of lung cancer using a combination of an anti-pd-1 antibody and another anti-cancer agent
AU2018241774A1 (en) Combination of an anti-PD-L1 antibody and a DNA-PK inhibitor for the treatment of cancer
KR20220024540A (ko) 암 환자에서의 항종양 면역의 증진을 위한 환자 선택
WO2017058754A1 (en) Combination therapy for treatment of hematological cancers and solid tumors
EP4168008B1 (en) A combination of belzutifan and lenvatinib for use in treating cancer
JP7504106B2 (ja) がんの処置のための組合せ物
CN110769857A (zh) 包含靶向治疗剂的联合疗法
CN117413049A (zh) 用于癌症治疗的分枝杆菌
CN115667552A (zh) 与对局部晚期或转移性尿路上皮癌中的免疫疗法敏感性相关的肿瘤突变负荷
US20240100021A1 (en) Combination Therapy Schedules to Treat Cancer
US20220257777A1 (en) Hsp90-binding conjugates and combination therapies thereof
US20210355223A1 (en) Combinations for Treating Cancer
Weller et al. New Approaches to Brain Tumor Therapy
HK40006436A (en) Use of glutamate modulating agents with immunotherapies to treat cancer
HK40006436B (en) Use of glutamate modulating agents with immunotherapies to treat cancer

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination